Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-13

Clinical Trial Update: 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine in healthy infants; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2015-03-13